EZH2 and mesothelioma: In addition, the combined targeting of EZH2 and an enzyme upstream in the mevalonate pathway, i.e., HMG-coenzyme A (CoA) by lovastatin, also results in reduced survival of BAP1-deficient mesothelioma cells (Figures S5G and S5H).